摘要:
The present invention concerns an improved process of making d4T from 5-MU. Another aspect of the invention relates to useful intermediates produced during the process.
摘要:
A process for preparing AZT and comprising the steps of:a) reacting a 2'-halo-5'-protected pyrimidinyl 2'-deoxyribonucleoside having a 3'-sulfonyl group with tributyl tin hydride and catalytic amount of azobisisobutyronitrile in an ether, ester, or ketone solvent to yield a dehalogenated pyrimidinyl 2'-deoxyribonucleoside; followed byb) reacting said dehalogentated pyrimidinyl 2'-deoxynucleoside formed in step (a) with a base, a lithium salt, and an azide salt to yield a 5'-protected pyrimidinyl 3'-dideoxy-3'-azido-ribonucleoside; andc) deprotecting the nucleoside derivative of step (b) to yield 3'-dideoxy-3'-azidothymidine.
摘要:
An economical process, amenable to large-scale production, is disclosed for the preparation of 2',3'-didehydro-3'-deoxythymidine (d4T) from 5-methyluridine. The process employs a novel, 5'-,acyl-2'.alpha.-halo-3'.alpha.-alkanesulfonylthymidine intermediate as well as a highly efficient and practical deprotection, isolation and purification procedure for the d4T product.
摘要:
A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds can be useful as factor Xa inhibitors.
摘要:
A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds can be useful as factor Xa inhibitors.
摘要:
A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below, as well as the corresponding pyrazoles, from appropriate phenyl hydrazines is described. These compounds can be useful as factor Xa inhibitors.
摘要:
The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or —C(═O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing pharmaceutical compositions for treating p38 kinase related conditions and/or in methods of treating conditions associated with the activity of p38 kinase in a patient.
摘要翻译:本发明涉及具有下式的化合物及其药学上可接受的盐,前体药物,溶剂合物,异构体和/或其水合物,其中Q是任选取代的苯基,吡啶基,哒嗪基,嘧啶基或吡嗪基; R 2是如本文所定义的烷基或氨基; 和Z是任选取代的恶二唑基或-C(-O)NR 6,其中R 6是低级烷基或环丙基。 该化合物在制备用于治疗p38激酶相关病症的药物组合物和/或治疗与患者中p38激酶活性相关的病症的方法中令人惊奇地有利。
摘要:
The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.
摘要:
The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or —C(═O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing pharmaceutical compositions for treating p38 kinase related conditions and/or in methods of treating conditions associated with the activity of p38 kinase in a patient.